Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Jun;55(6):258-63.

Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. Prothiaden Collaborative Study Group

J M Ferguson  1 , J Mendels, N R Manowitz
Affiliations
  • PMID: 8071282
Clinical Trial

Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. Prothiaden Collaborative Study Group

J M Ferguson et al. J Clin Psychiatry. 1994 Jun.

Abstract

Background: The tricyclic antidepressant dothiepin is well established in Europe, but clinical experience with the drug in the United States is limited.

Method: In a 10-week, multicenter, randomized, double-blind, placebo-controlled study in the United States, the efficacy and tolerability of dothiepin and doxepin (both administered as a 150-mg nightly dose) were compared in 579 outpatients with major depression.

Results: Patients in both active treatment groups showed significant improvements in depressive symptoms, associated anxiety, and sleep parameters compared with the placebo-treated group. The adverse effect profile of dothiepin was superior to that of doxepin, particularly with respect to drowsiness, weight gain, and increased appetite.

Conclusion: These results confirm that dothiepin is useful when a tricyclic agent is indicated for the treatment of depression.

PubMed Disclaimer

Publication types